Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Liabilities and Shareholders Equity (2023 - 2026)

ArriVent BioPharma has reported Liabilities and Shareholders Equity over the past 4 years, most recently at $349.3 million for Q1 2026.

  • Quarterly results put Liabilities and Shareholders Equity at $349.3 million for Q1 2026, up 62.09% from a year ago — trailing twelve months through Mar 2026 was $1.3 billion (up 17.08% YoY), and the annual figure for FY2025 was $333.2 million, up 21.18%.
  • Liabilities and Shareholders Equity reached $349.3 million in Q1 2026 per AVBP's latest filing, up from $333.2 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $349.3 million in Q1 2026 and bottomed at $163.1 million in Q4 2023.
  • Median Liabilities and Shareholders Equity over the past 4 years was $300.8 million (2024), compared with a mean of $286.1 million.
  • The largest annual shift saw Liabilities and Shareholders Equity soared 68.57% in 2024 before it plummeted 34.27% in 2025.
  • Over 4 years, Liabilities and Shareholders Equity stood at $163.1 million in 2023, then skyrocketed by 68.57% to $274.9 million in 2024, then rose by 21.18% to $333.2 million in 2025, then grew by 4.84% to $349.3 million in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for AVBP at $349.3 million in Q1 2026, $333.2 million in Q4 2025, and $326.6 million in Q3 2025.